BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. 1995

T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Department of Clinical Pharmacology, Schering-Plough Research Institute, Schering-Plough Corporation, Kenilworth, New Jersey, USA.

The steady-state pharmacokinetic profile of isosorbide-5-mononitrate (5-ISMN) after oral administration of an extended-release tablet formulation of 5-ISMN 60 mg or 120 mg once a day was compared with that after administration of isosorbide dinitrate (ISDN) 40 mg every 6 hours, in a randomized, open-label, three-way crossover trial in 24 healthy men. After oral administration of extended-release 5-ISMN 60 mg or 120 mg once daily, 5-ISMN was slowly absorbed, reaching mean peak plasma concentrations of 557 and 1151 ng/mL, respectively, in approximately 3 hours. Plasma concentrations of 5-ISMN were dose proportional between 60 mg and 120 mg. After oral administration of ISDN 40 mg every 6 hours, a mean peak plasma 5-ISMN concentration of 806 ng/mL was achieved in less than 2 hours (mean time to reach the maximum plasma concentration was 1.5 hours). The mean plasma apparent elimination half-life of 5-ISMN was 6.2 hours after extended-release 5-ISMN administration and 7.1 hours after ISDN. Although the maximum plasma concentration was higher and the minimum plasma concentration was lower after administration of extended-release 5-ISMN 120 mg once daily compared with ISDN 40 mg every 6 hours, there was no significant difference (P > 0.05) in the "bioavailability" of 5-ISMN between these two treatments. The most commonly reported adverse events in these "nitrate-naive" subjects were headache, dizziness, nausea, and vomiting; these were dose related and their incidence decreased with repeated exposure.

UI MeSH Term Description Entries
D007548 Isosorbide Dinitrate A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action. Cardonit 40,Dilatrate,Iso-Bid,Isodinit,Isoket,Isoket Retard-120,Isomak R,Isordil,Isotrate,Nitrosorbide,Sorbitrate,Sorbonit,Dinitrate, Isosorbide,Iso Bid,IsoBid,Isoket Retard 120,Isoket Retard120
D008297 Male Males
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
April 1991, The Canadian journal of cardiology,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
September 1989, International journal of clinical pharmacology, therapy, and toxicology,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
[Isosorbide-5-mononitrate. A metabolite of isosorbide dinitrate].
June 1985, Ugeskrift for laeger,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Saliva concentrations of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate.
May 1984, British journal of clinical pharmacology,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
October 1997, Biological & pharmaceutical bulletin,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
[Nitrite and methemoglobin formation in dogs following oral isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate].
April 1981, Die Medizinische Welt,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Isosorbide dinitrate: pharmacokinetics after intravenous administration.
June 1982, Journal of pharmaceutical sciences,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
[Pharmacokinetics, effect and tolerance of isosorbide dinitrate and isosorbide-5-mononitrate in healthy persons].
April 1981, Die Medizinische Welt,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Isosorbide 5-mononitrate pharmacokinetics.
January 1987, Cardiology,
T Kosoglou, and J E Patrick, and A Cohen, and E Radwanski, and D Christopher, and M B Affrime
Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.
January 1981, European journal of clinical pharmacology,
Copied contents to your clipboard!